Gut microbiota-mediated immunomodulation in tumor.

Area of Science:

• Oncology
• Immunology
• Microbiology

Background:

• Tumor immunity involves various cells crucial for antitumor therapy.
• The gut microbiota, trillions of microorganisms, impacts physiological processes beyond pathogen defense.
• Emerging research links gut microbiota to cancer, including oncogenesis, progression, and therapy response.

Purpose of the Study:

• To review the intricate relationship between the microbiome and tumor immunity.
• To explore the therapeutic potential of modulating gut microbiota in cancer treatment, particularly with immune checkpoint inhibitors (ICIs).

Main Methods:

• Literature review focusing on studies investigating microbiome-cancer interactions.
• Analysis of metagenome data comparing microbial composition in cancer patients versus healthy individuals.
• Examination of research on microbiome modulation and its effect on antitumor therapies.

Main Results:

• Significant differences in gut microbial composition exist between cancer patients and healthy individuals.
• Modulating the gut microbiome shows potential to improve therapeutic responses to immune checkpoint inhibitors (ICIs).
• The microbiome appears to regulate tumor immunosurveillance, impacting cancer pathogenesis and progression.

Conclusions:

• The gut microbiome plays a significant role in cancer immunity and progression.
• Targeting the gut microbiota offers a promising avenue for enhancing cancer immunotherapy efficacy.
• Further research is essential to translate these findings into clinical practice for cancer treatment.